Postdoctoral research, molecular and statistical population/quantitative genetics, Human Genetics Center, University of Texas, Houston, TX, 1997
PhD, quantitative genetics, University of Oregon, Eugene, OR, 1995
MS, mathematical statistics, University of Oregon, Eugene, OR, 1995
MS, ecology and entomology, Peking University, Beijing, P. R. China, 1990
BS, ecology and environmental biology, Peking University, Beijing, P. R. China, 1988
Dr. Hong-Wen Deng is a geneticist with extensive multi- and inter-disciplinary research experience and expertise in biostatistics and bioinformatics methodology research, genomics, transcriptomics, epigenomics, proteomics, genetic epidemiology, complex traits and diseases (especially osteoporosis), system biology, endocrinology, bone biology and recently metagenomics. Deng’s work is published in more than 500 peer-reviewed publications including journals such as Nature, New England Journal of Medicine, American Journal of Human Genetics, Endocrine Review, Plos Genetics, Human Molecular Genetics, Molecular Psychiatry, Bioinformatics, and Molecular Cell Proteomics. As of 2016, these publications have been cited more than16,000 times and his H-index is 65 and i10 index is 359. Deng’s primary research interests include all those areas that are related addressing the question: What and how genetic and environmental factors incur higher risk of, or better protection against, complex diseases, such as osteoporosis, in different sex and ethnic groups. We are most interested in generating, analyzing and integrating big data of various omics in vivo in humans. The purpose is to elucidate how DNA variants affect gene expression/regulation and protein expression/modification in the form of functional networks/modules/pathways and how the knowledge gained on these molecular mechanisms in humans would translate into better prediction/intervention/precision medicine and drug development.
- Member, Genetics Society of American
- Member, American Society of Human Genetics (ASHG)
- Member, American Society for Bone and Mineral Research (ASBMR)
- Member, International Genetic Epidemiology Society
- Member, Great Plains States Society for Molecular Biology and Genetics
- Member, International Chinese Hard Tissue Society (ICHTS)
- Member, International Society of Musculoskeletal and Neuronal Interactions (ISMNI)
- Member, International Society of Clinical Densitometry (ISCD)
Level of Instruction:
Our research group is interested in genetic dissection of human complex diseases using the state-of-the-art multi- and inter-disciplinary approaches of genomic technologies, and statistical and bioinformatical methods. The complex disease we are focusing on is osteoporosis, which is a prevalent, debilitating disorder characterized by bone fragility and an increased risk of low-trauma fractures. The approaches we are using involve genome-wide association analyses, genome-wide transcriptome analyses, proteome-wide protein expression profiling and in vivo and in vitro functional analyses of specific genes of interest. Currently, we are funded by several NIH grants for genetic, genomic and proteomic research of osteoporosis, including a P50 Specialized Center grant (1 P50 AR055081-01) for studying osteoporosis using the "genomic convergence analyses" approach.
Using the same genomic strategies, we are extending our research to other human complex diseases, including obesity, sarcopenia and periodontitis, and other human complex traits, including age at menarche/menopause and behavior traits, e.g., smoking, drinking and exercise. We are also extending our research of complex diseases from genome to epigenome, e.g., we are performing epigenome-wide profiling of osteoporosis at micro-RNA, DNA phosphorylation and histone modification levels. In particular, we are interested in developing novel statistical methods and bioinformatics tools for analyzing and managing large, complex datasets in genomic and epigenomic research.
Through Louisiana Osteoporosis Study (LOS), we are building a large research cohort and database for human complex disease studies. The LOS will enroll >20,000 subjects of different ethnicities in New Orleans, Baton Rouge and their surrounding areas. Each subject will be phenotyped for body composition (including bone mineral density, lean and fat mass), muscle function, and blood pressure etc., and assayed for important health-related and life-style information. Their blood samples will be collected for extraction of DNA, RNA and proteins and for cell isolation and biobanking. The LOS will become a sample pool for selecting subjects of extreme phenotypes (e.g., extremely high vs. low bone mass) for our ongoing funded and future genomic and epigenomic studies.
View Dr. Deng's publications at his NCBI profile page.